Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study
Élie Azoulay(Hôpital Saint-Louis), Kevin Rakszawski, Cécile Borel, Christian Récher(Institut universitaire du cancer de Toulouse Oncopole), Stéphanie Harel(Hôpital Saint-Louis), Julien Leroy(Université de Bordeaux), Julio Delgado(Departament de Salut), Sara Fernández(Oslo University Hospital), Faézeh Legrand(Centre Hospitalier Universitaire de Besançon), Bertrand Arnulf(Université Paris Cité), Muriel Picard(Institut universitaire du cancer de Toulouse Oncopole), Roberta Di Blasi(Assistance Publique – Hôpitaux de Paris), Adel Maamar(Centre Hospitalier Universitaire de Rennes), Didier Blaise(Institut Paoli-Calmettes), Louis Voigt(Memorial Sloan Kettering Cancer Center), Nahéma Issa(Bordeaux Population Health), Michael Joannidis(Innsbruck Medical University), Florence Rabian(Assistance Publique – Hôpitaux de Paris), Lara Zafrani(Inserm), Sandrine Valade(Inserm), Catherine Thiéblemont(Université Paris Cité), Djamel Mokart(Inserm), Anne Huynh(Institut universitaire du cancer de Toulouse Oncopole), Victoria Metaxa(Apple (Israel)), Éric Mariotte(Hôpital Saint-Louis), Valentín Ortiz‐Maldonado(Hospital Clínic de Barcelona), Philippe R. Bauer(Mayo Clinic in Florida), Alice Gallo de Moraes(Mayo Clinic), Boris Böll(University Hospital Cologne), Andry Van de Louw(Penn State Milton S. Hershey Medical Center), Christian Chabannon(Inserm), Sanjay Chawla(Memorial Sloan Kettering Cancer Center), Michaël Darmon(Inserm), Kada Klouche(Centre National de la Recherche Scientifique), Laveena Munshi(University of Toronto), Nicolas Boissel(Inserm), Gennadii M. Galstian, Florent Wallet(Université Claude Bernard Lyon 1), Gabriel Moreno‐González(Bellvitge University Hospital), Pleun Hemelaar(Radboud University Nijmegen), Jakob Rudzki, Édouard Forcade(Hôpital Cardiologique du Haut-Lévêque), François‐Xavier Gros, Pedro Castro(Hospital Clínic de Barcelona), Anne‐Sophie Moreau(Assistance Publique – Hôpitaux de Paris), Virginie Lemiale(Assistance Publique – Hôpitaux de Paris), Bruno Lévy(Inserm), Sabine Fürst(Hotel Dieu Hospital), Peter Schellongowski(Charles University), Amélie Seguin
Cited by 105
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium
|Clinical Infectious Diseases|2019|2.8k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury
|Critical Care|2013|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k